NewSquare Capital’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

NewSquare Capital’s Portfolio VBIV Stock Details VBIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-12	Closed	-$39	–	924
2023 Q2	$39	Sell	12 -1	-8%	-$3	﹤0.01%	823
2023 Q1	$121	Hold	13	–	–	﹤0.01%	817
2022 Q4	$156	Buy	+13	New	+$229	﹤0.01%	750

Other funds holding VBIV

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GAI

General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

NewSquare Capital's VBIV Position: Q3 2023 in Review

NewSquare Capital sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q3 2023, closing a stake of 12 shares — an estimated $39 sold.

NewSquare Capital first reported a position in VBIV in Q4 2022 and held it in 3 quarters. The position peaked at $156 in Q4 2022. 37 funds tracked by Wall St. Rank hold VBIV as of Q3 2023.

NewSquare Capital reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q3 2023 after selling out during the quarter.
NewSquare Capital sold 12 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q3 2023, an estimated $39.
NewSquare Capital first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q4 2022 and held it in 3 quarters.
NewSquare Capital's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $156 in Q4 2022.
37 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q3 2023.

Based on NewSquare Capital's 13F filing for Q3 2023, filed 3 Nov 2023.